CAR T-Cell Therapy

Engineering T cells to boost the immune system has potential benefits beyond cancer treatment, including treatments for chronic inflammatory diseases such as hepatitis, HIV/AIDS, lupus, and arthritis. Companies are also investigating CAR T-cell therapy in organ transplantation to eliminate the need for lifelong immunosuppressants. The future is bright for CAR-T research, and BPS Bioscience continues to develop unique cell lines and other tools to help researchers create, evaluate, and enhance CAR-T cells for the improvement of human health.

BPS has developed stable, recombinant cell lines expressing cancer antigens at different expression levels--high, medium, or low expression. These cell lines are ideal to monitor the effectiveness of different CAR-T at detecting the target antigen expressed at different levels, which may relate to the time dependence of antigen expression. 

BPS also offers biotin-labeled versions of many of the antigens recognized by CAR-T cells, such as BCMA, CD19, CD22, CD123, CD38, and ROR1. These biotin-labeled proteins can bind to CAR-T cells and be detected by flow cytometry using PE-streptavidin, in order to verify that the CAR-T cell is recognizing and binding the specific cancer antigen. In addition to our product portfolio, we also offer custom CAR-T cell development services. Contact us to learn more about how we can help accelerate your CAR-T research.